Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | S. Murphy | F. Andreotti | M. O’Donoghue | P. Merlini | O. Yin | C. Ruff | Thomas A. Zelniker | Jeong-Gun Park | M. Ardissino | H. Lanz
[1] G. Lip,et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study , 2012, BMJ : British Medical Journal.
[2] C. Murray,et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.
[3] Marco Proietti,et al. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. , 2015, International journal of cardiology.
[4] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[5] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[6] S. Yusuf,et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.
[7] E. Benjamin,et al. Atrial fibrillation in women: treatment , 2017, Nature Reviews Cardiology.
[8] Dhanunjaya R. Lakkireddy,et al. Atrial Fibrillation: JACC Council Perspectives. , 2020, Journal of the American College of Cardiology.
[9] E. Antman,et al. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. , 2016, The American journal of medicine.
[10] D. Atar,et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. , 2015, European heart journal.
[11] E. Antman,et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial , 2020, Thrombosis and Haemostasis.
[12] J. Halperin,et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. , 2006, European heart journal.
[13] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[14] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[15] Theresa M Beckie,et al. Council on cardiovascular and stroke nursing. , 2013, The Journal of cardiovascular nursing.
[16] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[17] E. Antman,et al. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial , 2018, Circulation.
[18] S. Stewart,et al. Women Versus Men with Chronic Atrial Fibrillation: Insights from the Standard Versus Atrial Fibrillation spEcific managemenT studY (SAFETY) , 2013, PloS one.
[19] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[20] S. Connolly,et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective , 2011, Thrombosis and Haemostasis.
[21] E. Rahme,et al. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation , 2015, Circulation. Cardiovascular quality and outcomes.
[22] G. Lip,et al. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? , 2018, Circulation.
[23] J. Tolstrup,et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.
[24] E. Antman,et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. , 2019, European heart journal.
[25] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[26] E. Antman,et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.
[27] Gustavo Saposnik,et al. Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2014, Stroke.
[28] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[29] L. Allen,et al. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. , 2016, JAMA cardiology.
[30] K. Rathgen,et al. Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects , 2008, Clinical pharmacokinetics.